ImClone Systems Incorporated (Nasdaq: IMCL) is a biopharmaceutical company dedicated to developing breakthrough biologic medicines in the area of oncology. The Company has utilized the many advances made in the fields of molecular biology, oncology, genomics and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development.
ImClone Systems’ goal is to become a fully-integrated biopharmaceutical company that has the capability and resources to take its novel pipeline compounds and develop them from the research and development stage through to commercial manufacture, marketing and sales.
HISTORY
The Company was founded in 1984 and in 1986, opened its laboratories at 180 Varick Street in New York City. In its early years, the Company focused on immunology-based diagnostics and infectious disease vaccines. This focus resulted in two FDA approved diagnostics and several vaccine research programs, all of which have been licensed to pharmaceutical companies. During the early nineties, the Company’s focus shifted from diagnostics and infectious disease to the development of a pipeline of innovative, biologic compounds in the area of oncology.
OPERATIONS
ImClone Systems operates in three locations - its corporate and scientific headquarters at 180 Varick Street in New York City, which houses the Company's research and executive offices, its chemistry facility in Brooklyn, New York and its campus in Branchburg, New Jersey. The Branchburg facility is home to the manufacturing, product development, finance, clinical, regulatory and quality assurance and commercial operations departments.
